Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis

Company Overview

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Key Stats

• Today's Range: $3.19 to $4.64
• 50-Day Range: $3.55 to $5.48
• 52-Week Range: $3.19 to $21.40
• Volume: 646,276 shs
• Average Volume: 75,501 shs
• Market Capitalization: $19.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Hold

Neuphoria Therapeutics Stock Analysis - MarketRank™

Neuphoria Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 252nd out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Neuphoria Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Neuphoria Therapeutics has a consensus price target of $21.00, representing about 491.5% upside from its current price of $3.55.

Amount of Analyst Coverage

Neuphoria Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neuphoria Therapeutics are expected to grow in the coming year, from ($4.07) to ($2.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuphoria Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuphoria Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neuphoria Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.43% of the float of Neuphoria Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Neuphoria Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neuphoria Therapeutics has recently decreased by 37.48%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuphoria Therapeutics does not currently pay a dividend.

Dividend Growth

Neuphoria Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.57

News Sentiment

Neuphoria Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Neuphoria Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Neuphoria Therapeutics is held by insiders.

Percentage Held by Institutions

15.90% of the stock of Neuphoria Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 7/01/2026
• Next Earnings (Estimated): 9/02/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NEUP
• Previous Symbol: NASDAQ:NEUP
• CIK: 1191070
• Web: www.bionomics.com.au
• Phone: 61-8-8150-7400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Neuphoria Therapeutics: $21.00
• High Price Target: $35.00
• Low Price Target: $7.00
• Potential Upside/Downside: +491.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$370 thousand
• Net Margins: N/A
• Pretax Margin: -40.58%
• Return on Equity: -76.93%
• Return on Assets: -54.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.31
• Quick Ratio: 14.31

Sales & Book Value

• Annual Sales: $15.65 million
• Price / Sales: 1.22
• Cash Flow: $0.13 per share
• Price / Cash Flow: 28.04
• Book Value: $10.11 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 5,400,000
• Free Float: 5,324,000
• Market Cap: $19.17 million
• Optionable: N/A
• Beta: 0.74